December 2002
Volume 43, Issue 13
Free
ARVO Annual Meeting Abstract  |   December 2002
T Cells From HLA-DRB1*0405 Vogt-Koyanagi-Harada Patients Recognize Melanocyte Epitopes With High Avidity and a T1-Type Cytokine Profile
Author Affiliations & Notes
  • FM Damico
    Dept Ophthalmology Univ São Paulo Med School São Paulo Brazil
  • E Cunha-Neto
    Lab Immunology Heart Institute (InCor) Univ São Paulo Med School São Paulo Brazil
  • AC Goldberg
    Lab Immunology Heart Institute (InCor) Univ São Paulo Med School São Paulo Brazil
  • LK Iwai
    Lab Immunology Heart Institute (InCor) Univ São Paulo Med School São Paulo Brazil
  • ML Marin
    Lab Immunology Heart Institute (InCor) Univ São Paulo Med School São Paulo Brazil
  • J Kalil
    Lab Immunology Heart Institute (InCor) Univ São Paulo Med School São Paulo Brazil
  • JH Yamamoto
    Dept Ophthalmology Univ São Paulo Med School São Paulo Brazil
  • Footnotes
    Commercial Relationships   F.M. Damico, None; E. Cunha-Neto, None; A.C. Goldberg, None; L.K. Iwai, None; M.L. Marin, None; J. Kalil, None; J.H. Yamamoto, None. Grant Identification: FAPESP 98/13783-1 and 99/07319-3
Investigative Ophthalmology & Visual Science December 2002, Vol.43, 1530. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      FM Damico, E Cunha-Neto, AC Goldberg, LK Iwai, ML Marin, J Kalil, JH Yamamoto; T Cells From HLA-DRB1*0405 Vogt-Koyanagi-Harada Patients Recognize Melanocyte Epitopes With High Avidity and a T1-Type Cytokine Profile . Invest. Ophthalmol. Vis. Sci. 2002;43(13):1530.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : VKH is an autoimmune disease targeted against melanocytes in susceptible individuals. We have been studying the significance of the susceptibility allele HLA-DRB1*0405 and melanocyte proteins. Purpose: To analyze the PBMC proliferative response against human melanoma lysate and to further analyze the response to peptides from melanocyte proteins, and peptide-induced-IFN-γ, IL-4 and IL-5 secretion in VKH patients and controls presenting DRB1*0405 or not. Methods: PBMC of 34 patients and 17 controls were tested against human melanoma lysate and 29 synthetic peptides from tyrosinase, tyrosinase-related protein (Trp)-1, Trp-2 and Pmel-17 in proliferation and cytokine assays (ELISA). Peptides were selected based on their predicted binding chance to DRB1*0405 and to the non-disease-related DR15 using the software TEPITOPE. Individuals were analyzed according to their HLA-DR typing: DRB1*0405 (12 patients and 9 controls) and other HLA (22 patients and 8 controls). Results: Patients (44%) recognized melanoma lysate while controls did not (p<.01). DRB1*0405 patients recognized peptides at lower concentrations than non-DRB1*0405 patients (p<.05); furthermore, they recognized 61% of peptides and HLA-matched controls 32% (p=.05). Some peptides, mainly derived from Trp-1, were preferentially recognized by DRB1*0405 patients. An inverse correlation was observed between peptide predicted binding score and peptide-induced IFN-γ secretion concerning DRB1*0405-binder peptides and DRB1*0405 patient responses. Peptide-induced IFN-γ secretion was present in patients and controls, while only controls secreted IL-4 (p<.01). IL-5 secretion was not observed in any group. There was no correlation between peptide recognition and disease severity and activity. Conclusion: Our data suggest that the pathogenic T cells involved in VKH are T1-type. T cells from HLA-DRB1*0405 patients recognize cryptic HLA-DRB1*0405-restricted melanocyte epitopes with high avidity. This peculiar fashion of response points to the importance of the HLA-DRB1*0405 and the role of melanocyte proteins in the pathogenesis of the disease.

Keywords: 612 uveitis-clinical/animal model • 327 autoimmune disease • 463 melanocytes 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×